# Neuraxis, INC: overview NRXS · NYSE · CIK 1933567 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nrxs.md) · [Financials](/companies/nrxs/financials.md) · [Filings](/companies/nrxs/filings.md) · [Insiders](/companies/nrxs/insiders.md) Latest reported revenue: [$1.9m](/filings/0001493152-26-036978.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-036978). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [667](/filings/0001493152-25-021547.md) | [761 d](/filings/0001493152-26-011505.md) | [896](/filings/0001493152-26-022384.md) | [894](/filings/0001493152-26-036978.md) | [811](/filings/0001493152-25-021547.md) | [968 d](/filings/0001493152-26-011505.md) | [1,608](/filings/0001493152-26-022384.md) | [1,929](/filings/0001493152-26-036978.md) | | Gross margin | % | [85.4%](/filings/0001493152-25-021547.md) | [86.2% d](/filings/0001493152-26-011505.md) | [84.4%](/filings/0001493152-26-022384.md) | [83.6%](/filings/0001493152-26-036978.md) | [83.3%](/filings/0001493152-25-021547.md) | [85.4% d](/filings/0001493152-26-011505.md) | [86.4%](/filings/0001493152-26-022384.md) | [85.9%](/filings/0001493152-26-036978.md) | | Operating margin | % | [(247.7%)](/filings/0001493152-25-021547.md) | [(192.7%) d](/filings/0001493152-26-011505.md) | [(256.2%)](/filings/0001493152-26-022384.md) | [(192.1%)](/filings/0001493152-26-036978.md) | [(258.8%)](/filings/0001493152-25-021547.md) | [(177.3%) d](/filings/0001493152-26-011505.md) | [(108.3%)](/filings/0001493152-26-022384.md) | [(110.2%)](/filings/0001493152-26-036978.md) | | Net margin | % | [(263.3%)](/filings/0001493152-25-021547.md) | [(190.2%) d](/filings/0001493152-26-011505.md) | [(254.4%)](/filings/0001493152-26-036978.md) | [(189.1%)](/filings/0001493152-26-036978.md) | [(261.6%)](/filings/0001493152-25-021547.md) | [(176.5%) d](/filings/0001493152-26-011505.md) | [(109.5%)](/filings/0001493152-26-036978.md) | [(108.1%)](/filings/0001493152-26-036978.md) | | Diluted EPS | $ per share | [(0.25)](/filings/0001493152-25-021547.md) | not reported | [(0.33)](/filings/0001493152-26-022384.md) | [(0.22)](/filings/0001493152-26-036978.md) | [(0.24)](/filings/0001493152-25-021547.md) | not reported | [(0.18)](/filings/0001493152-26-022384.md) | [(0.19)](/filings/0001493152-26-036978.md) | | Free cash flow | $k | [(1,397) d](/filings/0001493152-25-021547.md) | [(1,758) d](/filings/0001493152-26-011505.md) | [(1,622)](/filings/0001493152-26-022384.md) | [(1,475) d](/filings/0001493152-26-036978.md) | [(1,428) d](/filings/0001493152-25-021547.md) | [(1,940) d](/filings/0001493152-26-011505.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $k | [2,685](/filings/0001493152-24-014832.md) | [2,460](/filings/0001493152-25-010984.md) | [2,686](/filings/0001493152-26-011505.md) | [3,569](/filings/0001493152-26-011505.md) | | Gross margin | % | [88.9%](/filings/0001493152-24-014832.md) | [87.7%](/filings/0001493152-25-010984.md) | [86.5%](/filings/0001493152-26-011505.md) | [84.2%](/filings/0001493152-26-011505.md) | | Operating margin | % | [(125.6%)](/filings/0001493152-24-014832.md) | [(270.9%)](/filings/0001493152-25-010984.md) | [(266.5%)](/filings/0001493152-26-011505.md) | [(219.4%)](/filings/0001493152-26-011505.md) | | Net margin | % | [(178.0%)](/filings/0001493152-24-014832.md) | [(594.6%)](/filings/0001493152-25-010984.md) | [(306.8%)](/filings/0001493152-26-011505.md) | [(218.5%)](/filings/0001493152-26-011505.md) | | Diluted EPS | $ per share | [(2.77)](/filings/0001493152-24-014832.md) | [(4.50)](/filings/0001493152-25-010984.md) | [(1.22)](/filings/0001493152-26-011505.md) | [(0.95)](/filings/0001493152-26-011505.md) | | Free cash flow | $k | [(2,299)](/filings/0001493152-24-014832.md) | [(6,725)](/filings/0001493152-25-010984.md) | [(6,126)](/filings/0001493152-26-011505.md) | [(6,464)](/filings/0001493152-26-011505.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nrxs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $3.8m | 519,938 | | Added +119,938 | | [Rosalind Advisors, Inc.](/funds/1622627.md) | 2026-06-30 | $3.0m | 508,055 | | Added +221,917 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.5m | 335,793 | | Added +109,926 | | [MONEY CONCEPTS CAPITAL CORP](/funds/716851.md) | 2026-06-30 | $1.7m | 228,029 | | Added +2,474 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.2m | 169,400 | | Added +92,446 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $941.2k | 128,755 | | Added +50,060 | | [PARSONS CAPITAL MANAGEMENT INC/RI](/funds/1018674.md) | 2026-06-30 | $861.2k | 117,808 | | Added +1,082 | | [Panoramic Capital, LLC](/funds/1950490.md) | 2026-06-30 | $840.6k | 115,000 | | Reduced −75,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $704.7k | 96,361 | | Added +3,256 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $621.7k | 85,053 | | New +85,053 | ## Recent filings [All 193 filings](/companies/nrxs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-14 | 21:00 ET | [8-K](/filings/0001493152-26-047034.md) | 8.01 Other events | 0001493152-26-047034 | | 2026-08-19 | 21:00 ET | [8-K](/filings/0001493152-26-039247.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001493152-26-039247 | | 2026-08-11 | 11:00 ET | [10-Q](/filings/0001493152-26-036978.md) | Quarterly report, period 2026-06-30 | 0001493152-26-036978 | | 2026-07-10 | 11:00 ET | [8-K](/filings/0001493152-26-032769.md) | 8.01 Other events | 0001493152-26-032769 | | 2026-06-12 | 20:50 ET | [8-K](/filings/0001493152-26-028489.md) | 5.07 Shareholder vote results | 0001493152-26-028489 | | 2026-05-12 | 11:00 ET | [10-Q](/filings/0001493152-26-022384.md) | Quarterly report, period 2026-03-31 | 0001493152-26-022384 | | 2026-04-28 | 21:00 ET | [DEF 14A](/filings/0001140361-26-017498.md) | Proxy statement, period 2026-06-10 | 0001140361-26-017498 | | 2026-04-22 | 20:54 ET | [8-K](/filings/0001493152-26-018580.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-018580 | | 2026-04-21 | 21:28 ET | [8-K](/filings/0001493152-26-018376.md) | 2.02 Results of operations | 0001493152-26-018376 | | 2026-03-19 | 11:00 ET | [10-K](/filings/0001493152-26-011505.md) | Annual report, period 2025-12-31 | 0001493152-26-011505 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-011505.md), filed Mar 19, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ec0b35e2-f8af-4183-99de-e9e05d22dd3f) ## About the filer - CIK: 1933567 - Tickers: NRXS - Exchange: NYSE - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.